Time filter

Source Type

Chiorean R.,Clinical University Hospital of Dermatovenereology | Chiorean R.,Albert Ludwigs University of Freiburg | Chiorean R.,The Oncological Institute Prof Dr Ion Chiricuta | Braicu C.,Albert Ludwigs University of Freiburg | And 5 more authors.
Breast | Year: 2013

Triple negative breast cancer is a heterogeneous group of tumors, lacking the expression of estrogen, progesterone and HER-2 receptors. As frequency, it accounts about 15-20% of all breast cancers. Although in the last years there was a "boom" in publishing over this issue, multiple molecular classifications being elaborated, "the triple negative breast cancer odyssey " is still far away from ending, as the complicated molecular pathways of pathogenesis and drug resistance mechanisms remain yet insufficiently explored. The aim of this review is presentation of molecular signatures that could predict outcome and drug resistance in triple negative breast cancer. © 2013 Elsevier Ltd.

Tomuleasa C.,University of Medicine and Pharmacy, Cluj-Napoca | Braicu C.,University of Medicine and Pharmacy, Cluj-Napoca | Irimie A.,University of Medicine and Pharmacy, Cluj-Napoca | Craciun L.,University of Medicine and Pharmacy, Cluj-Napoca | And 2 more authors.
International Journal of Nanomedicine | Year: 2014

Nanoparticles have displayed considerable promise for safely delivering therapeutic agents with miscellaneous therapeutic properties. Current progress in nanotechnology has put forward, in the last few years, several therapeutic strategies that could be integrated into clinical use by using constructs for molecular diagnosis, disease detection, cytostatic drug delivery, and nanoscale immunotherapy. In the hope of bringing the concept of nanopharmacology toward a viable and feasible clinical reality in a cancer center, the present report attempts to present the grounds for the use of cell-free nanoscale structures for molecular therapy in experimental hematology and oncology. © 2014 Tomuleasa et al.

Gherman C.,The Oncology Institute Prof Dr Ion Chiricuta | Gherman C.,University of Medicine and Pharmacy, Cluj-Napoca | Braicu O.L.,University of Medicine and Pharmacy, Cluj-Napoca | Braicu O.L.,The Oncological Institute Prof Dr Ion Chiricuta | And 11 more authors.
Molecular and Cellular Biochemistry | Year: 2016

Ovarian cancer is a highly aggressive pathology, displaying a poor prognosis and chemoresistance to classical therapy. The present study was conducted to evaluate the effect of caffeic acid phenethyl ester (CAPE) on survival of ovarian cancer cell lines, A2780 (sensitive to cisplatin) and A2780cis (resistant to cisplatin). MTT assay was used to evaluate cell viability, while the apoptotic processes were examined by flow cytometry and qRT-PCR. A reduction of cell proliferation and activation of the apoptosis was observed in both cell lines. qRT-PCR evaluation demonstrated the activation of the pro-apoptotic genes (BAD, CASP8, FAS, FADD, p53) in both cell lines. The limited therapeutic effect in A2780 cells is explained by the activation of epithelial–mesenchymal transition-related genes (ZEB1, ZEB2, or TGFBB1) as displayed by Ingenuity Network analysis. Overall data suggest that CAPE can be used as an alternative in sensitizing cells to chemotherapy. © 2016, Springer Science+Business Media New York.

Discover hidden collaborations